182 related articles for article (PubMed ID: 15196436)
1. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
[TBL] [Abstract][Full Text] [Related]
2. [Expression of zeta (zeta) chain in peripheral blood T lymphocytes and NK cells of children with idiopathic nephrotic syndrome (INS)--preliminary results].
Musiał K; Ciszak L; Kosmaczewska A; Szteblich A; Pawlak E; Zwolińska D; Frydecka I
Przegl Lek; 2006; 63 Suppl 3():208-10. PubMed ID: 16898532
[TBL] [Abstract][Full Text] [Related]
3. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
[TBL] [Abstract][Full Text] [Related]
4. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
6. Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients.
Eleftheriadis T; Kartsios C; Yiannaki E; Kazila P; Antoniadi G; Liakopoulos V; Markala D
Blood Purif; 2008; 26(4):317-21. PubMed ID: 18463433
[TBL] [Abstract][Full Text] [Related]
7. Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in haemodialysis patients.
Eleftheriadis T; Kartsios C; Yiannaki E; Antoniadi G; Kazila P; Pliakos K; Liakopoulos V; Markala D
Nephrology (Carlton); 2009 Aug; 14(5):471-5. PubMed ID: 19486472
[TBL] [Abstract][Full Text] [Related]
8. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma.
Cardi G; Heaney JA; Schned AR; Phillips DM; Branda MT; Ernstoff MS
Cancer Res; 1997 Aug; 57(16):3517-9. PubMed ID: 9270022
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer.
Kono K; Ressing ME; Brandt RM; Melief CJ; Potkul RK; Andersson B; Petersson M; Kast WM; Kiessling R
Clin Cancer Res; 1996 Nov; 2(11):1825-8. PubMed ID: 9816136
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.
Nakagomi H; Petersson M; Magnusson I; Juhlin C; Matsuda M; Mellstedt H; Taupin JL; Vivier E; Anderson P; Kiessling R
Cancer Res; 1993 Dec; 53(23):5610-2. PubMed ID: 8242612
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?
Whiteside TL
Cancer Immunol Immunother; 2004 Oct; 53(10):865-78. PubMed ID: 15118842
[TBL] [Abstract][Full Text] [Related]
12. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer.
Ciszak L; Kosmaczewska A; Werynska B; Szteblich A; Jankowska R; Frydecka I
Oncol Rep; 2009 Jan; 21(1):173-84. PubMed ID: 19082459
[TBL] [Abstract][Full Text] [Related]
13. Lactoferrin-induced up-regulation of zeta (zeta) chain expression in peripheral blood T lymphocytes from cervical cancer patients.
Frydecka I; Zimecki M; Bocko D; Kosmaczewska A; Teodorowska R; Ciszak L; Kruzel M; Wlodarska-Polinsk J; Kuliczkowski K; Kornafel J
Anticancer Res; 2002; 22(3):1897-901. PubMed ID: 12168890
[TBL] [Abstract][Full Text] [Related]
14. T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations.
Garlie NK; Siebenlist RE; Lefever AV
J Urol; 2001 Jul; 166(1):299-303. PubMed ID: 11435890
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte therapy of renal cell carcinoma.
Dillman RO
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder.
Agarwal A; Verma S; Burra U; Murthy NS; Mohanty NK; Saxena S
Cancer Immunol Immunother; 2006 Jun; 55(6):734-43. PubMed ID: 16283306
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer.
Kuss I; Saito T; Johnson JT; Whiteside TL
Clin Cancer Res; 1999 Feb; 5(2):329-34. PubMed ID: 10037182
[TBL] [Abstract][Full Text] [Related]
19. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
[TBL] [Abstract][Full Text] [Related]
20. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
